Trends in drug-resistant tuberculosis in the United States, 1993-1996

M. Moore, I. M. Onorato, E. McCray and K. G. Castro
Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

CONTEXT: With the resurgence of tuberculosis (TB) disease in the late 1980s and early 1990s in the United States, multidrug-resistant (MDR) TB emerged as a serious challenge to TB control. In response, the Centers for Disease Control and Prevention in 1993 added drug susceptibility test results to the information collected for the national surveillance system to monitor trends in drug resistance. OBJECTIVE: To determine the extent of drug-resistant tuberculosis (TB) in the United States. DESIGN: Descriptive analysis of TB surveillance data. STUDY POPULATION: Patients reported to the national TB surveillance system as confirmed TB cases with culture-positive disease from 1993 through 1996 by the 50 states, New York City, and the District of Columbia (DC). MAIN OUTCOME MEASURE: Percentage of case patients with culture-positive disease whose isolates are resistant to specific anti-TB drugs. RESULTS: Overall resistance to at least isoniazid was 8.4%; rifampin, 3.0%; both isoniazid and rifampin (ie, MDR TB), 2.2%; pyrazinamide, 3.0%; streptomycin, 6.2%; and ethambutol hydrochloride, 2.2%. Rates of resistance were significantly higher for case patients with a prior TB episode. Among those without prior TB, isoniazid resistance of 4% or more was found in 41 states, New York City, and DC. A total of 1457 MDR TB cases were reported from 42 states, New York City, and DC; however, 38% were reported from New York City. Rates of isoniazid and streptomycin resistance were higher for cases among foreign-born compared with US-born patients [corrected] but rates of rifampin resistance and MDR TB were similar. Among US-born patients, resistance to first-line drugs, particularly rifampin monoresistance, was significantly higher among those with human immunodeficiency virus (HIV) infection. CONCLUSIONS: Compared with recent US surveys in 1991 and 1992, isoniazid resistance has remained relatively stable. In addition, the percentage of MDR TB has decreased, although the national trend was significantly influenced by the marked decrease in New York City. Foreign-born and HIV-positive patients and those with prior TB have higher rates of resistance. The widespread extent of isoniazid resistance confirms the need for drug susceptibility testing to guide optimal treatment of patients with culture-positive disease.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis.
Hazbon et al.
Antimicrob. Agents Chemother. 2006;50:2640-2649.
ABSTRACT | FULL TEXT  

Multidrug Resistance Among Persons With Tuberculosis in California, 1994-2003
Granich et al.
JAMA 2005;293:2732-2739.
ABSTRACT | FULL TEXT  

Single Nucleotide Polymorphisms in Genes Associated with Isoniazid Resistance in Mycobacterium tuberculosis
Ramaswamy et al.
Antimicrob. Agents Chemother. 2003;47:1241-1250.
ABSTRACT | FULL TEXT  

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Am. J. Respir. Crit. Care Med. 2003;167:603-662.
FULL TEXT  

Isoniazid Activation Defects in Recombinant Mycobacterium tuberculosis Catalase-Peroxidase (KatG) Mutants Evident in InhA Inhibitor Production
Wei et al.
Antimicrob. Agents Chemother. 2003;47:670-675.
ABSTRACT | FULL TEXT  

Global Drug-Resistance Patterns and the Management of Latent Tuberculosis Infection in Immigrants to the United States
Khan et al.
NEJM 2002;347:1850-1859.
ABSTRACT | FULL TEXT  

Oxidative Stress Increases Susceptibility of Mycobacterium tuberculosis to Isoniazid
Bulatovic et al.
Antimicrob. Agents Chemother. 2002;46:2765-2771.
ABSTRACT | FULL TEXT  

Limited Transmission of Multidrug-Resistant Tuberculosis Despite a High Proportion of Infectious Cases in Los Angeles County, California
NITTA et al.
Am. J. Respir. Crit. Care Med. 2002;165:812-817.
ABSTRACT | FULL TEXT  

Tuberculosis due to Environment, Biology, or Both?
Villarino and Clairy
Chest 2001;120:1435-1437.
FULL TEXT  

Identification of Rifampin-Resistant Mycobacterium tuberculosis Strains by Hybridization, PCR, and Ligase Detection Reaction on Oligonucleotide Microchips
Mikhailovich et al.
J. Clin. Microbiol. 2001;39:2531-2540.
ABSTRACT | FULL TEXT  

Treatment of Isoniazid-Resistant Tuberculosis in Southeastern Texas
Escalante et al.
Chest 2001;119:1730-1736.
ABSTRACT | FULL TEXT  

Tuberculosis Among Foreign-Born Persons in the United States, 1993-1998
Talbot et al.
JAMA 2000;284:2894-2900.
ABSTRACT | FULL TEXT  

Recall of Isoniazid Used for Antimicrobial Susceptibility Testing for Tuberculosis
JAMA 2000;284:1642-1643.
FULL TEXT  

Drug-resistant tuberculosis
Long
CMAJ 2000;163:425-428.
ABSTRACT | FULL TEXT  

Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected Persons: An International Randomized Trial
Gordin et al.
JAMA 2000;283:1445-1450.
ABSTRACT | FULL TEXT  

Survey of Drug Resistance of Mycobacterium tuberculosis in 3 Mexican States, 1997
Granich et al.
Arch Intern Med 2000;160:639-644.
ABSTRACT | FULL TEXT  

Severity prediction rules in community acquired pneumonia: a validation study
Lim et al.
Thorax 2000;55:219-223.
ABSTRACT | FULL TEXT  

Four-Month, Four-Drug Preventive Therapy for Inactive Pulmonary Tuberculosis
GOLDBERG et al.
Am. J. Respir. Crit. Care Med. 1999;160:508-512.
ABSTRACT | FULL TEXT  

Risk Factors for Rifampin-monoresistant Tuberculosis . A Case-Control Study
SANDMAN et al.
Am. J. Respir. Crit. Care Med. 1999;159:468-472.
ABSTRACT | FULL TEXT  

Pulmonary Tuberculosis: The Essentials
Leung
Radiology 1999;210:307-322.
FULL TEXT  

Pathogenic Mycobacterium tuberculosis Evades Apoptosis of Host Macrophages by Release of TNF-R2, Resulting in Inactivation of TNF-{alpha}
Balcewicz-Sablinska et al.
J. Immunol. 1998;161:2636-2641.
ABSTRACT | FULL TEXT  

Comparison of Three Molecular Assays for Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis
Watterson et al.
J. Clin. Microbiol. 1998;36:1969-1973.
ABSTRACT | FULL TEXT  

New Tuberculosis Drug Development . How Can We Do Better?
O'Brien and Vernon
Am. J. Respir. Crit. Care Med. 1998;157:1705-1707.
FULL TEXT  

Tuberculosis Morbidity--United States, 1997
JAMA 1998;279:1515-1516.
FULL TEXT  

Simultaneous Genotyping and Species Identification Using Hybridization Pattern Recognition Analysis of Generic Mycobacterium DNA Arrays
Gingeras et al.
Genome Res. 1998;8:435-448.
ABSTRACT | FULL TEXT  

FIGHTING TUBERCULOSIS IN THE 1990s
JWatch General 1997;1997:3-3.
FULL TEXT